Gemcitabine with or without Pitavastatin for Advanced Pancreatic Cancer
Treatments studied
Part of Cancer, Digestive system, Hormones & metabolism clinical trials.
This study tests whether adding pitavastatin (a cholesterol-lowering drug) to gemcitabine chemotherapy can help treat pancreatic cancer that cannot be surgically removed. You would join if your cancer hasn't grown worse after 2–4 rounds of gemcitabine.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Age 18 or older
- Histologically or cytologically confirmed metastatic, recurrent, or locally advanced pancreatic adenocarcinoma (cancer that has spread, come back, or cannot be surgically removed)
- Currently receiving gemcitabine-based chemotherapy for 2–4 cycles with stable or shrinking disease (no radiographic progression)
- Measurable disease on imaging per RECIST 1.1 criteria
- Adequate organ function (blood counts, liver, and kidney function within acceptable ranges)
- ECOG performance status 0–2 (able to carry out light activities)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of three medicines to see if they can slow down or shrink pancreatic cancer that has not responded to previous treatments or has come back. It might help if you are generally healthy and your cancer is advanced.
This trial tests a combination of an immunotherapy drug (adebrelimab) with two chemotherapy drugs (gemcitabine and nab-paclitaxel) for people with advanced pancreatic cancer that has progressed after prior treatment. The goal is to see if adding immunotherapy can help shrink tumors or slow the cancer down.
This trial studies a chemotherapy combination (albumin-bound paclitaxel and gemcitabine) as first treatment for pancreatic cancer that cannot be removed by surgery. It aims to improve outcomes by testing how well this treatment works in people with locally advanced or metastatic disease.
This trial tests a combination of three drugs—atebimetinib (a new targeted therapy), gemcitabine, and nab-paclitaxel (two standard chemotherapy drugs)—as a first treatment for pancreatic cancer that has spread beyond the pancreas. The goal is to see if adding atebimetinib helps patients live longer and feel better.
This trial tests whether adding a traditional Chinese herb (Astragalus) to a standard chemotherapy drug (gemcitabine) before surgery works better than gemcitabine alone for treating pancreatic cancer. People who can join will have locally advanced or borderline resectable cancer that hasn't spread to distant organs.
This trial studies whether adding canagliflozin to standard chemotherapy (gemcitabine) can slow pancreatic cancer that cannot be fully removed by surgery. It may help some people control the cancer for longer and improve how well treatment works.
Hear when a new Pancreatic cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.